Newly identified, highly selective FFA2-DREADD agonist which acts as a selective orthostatic agonist at the engineered hFFA2 (human free fatty acid2)-DREADD receptor and shows no activity at wild-type hFFA2, hFFA3 or mouse FFA2 receptors. Displays improved potency and comparable efficacy to the alternative hFFA2-DREADD activator sorbic acid in hFFA2-DREADD transgenic mice. In cells expressing the hFFA2-DREADD receptor, MOMBA inhibits forskolin-induced cAMP levels, reduces gut transit and induces a FFA2 specific concentration dependent release of GLP-in colonic crypts and GLP-1 and PYY secretion in intact colon. Active in vivo and orally bioavailable.
Solubility & Handling
Soluble in DMSO (100 mM), and in ethanol (100 mM)
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use